Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 17 October 2016 | By Michael Mezher
Particle contamination on the surface of breast implants made by Brazilian devicemaker Silimed poses, at worst, a "one in a million" risk to patients, according to a report released on Monday by the Dutch National Institute for Public Health and the Environment (RIVM).
Last fall, EU regulators suspended all CE certificates for Silimed devices after German notified body TÜV SÜD found man-made fibers on the surface of the company's implants.
After the inspection, Sientra, the largest US distributor of Silimed implants, briefly halted sales of Silimed devices, but resumed sales in January after a third-party review found the devices to be safe.
For its part, the US Food and Drug Administration (FDA) said it was taking a "cautionary approach" to monitoring the Silimed devices, but did not issue any safety alerts or recalls for the implants.
Now, in a report commissioned by regulators in the UK, Ireland, Belgium and the Netherlands, RIVM says the risk to patients from the presence of the fibers is minimal.
"The worst case scenario shows a chance of 1 in a million that adverse health effects may occur," writes RIVM.
In light of the findings, Medicines and Healthcare products Regulatory Agency (MHRA) Director of Devices John Wilkinson says his agency is "currently liaising with the European Independent Clinical Expert Advisory Group about the safety of these products and will carefully evaluate their advice before we reach a finalised position."
However, Wilkinson says, "There is no suggestion in the RIVM report that women who have Silimed breast implants should seek to have them explanted or that any additional clinical follow-up is required."
While the study did find fibers, now believed to be man-made mineral fibers such as glasswool and rockwool, consistent with those reported by TÜV SÜD on samples of the devices manufactured between 2009 and 2015, "It is safe to conclude that the fibre dose stemming from the breast implants is far below the limit that is considered acceptable for daily, lifelong occupational exposure. Thus, the likelihood that appreciable inflammation reactions will occur is very low," the report says.
Similarly, the report concludes that the risk of patients developing cancer as a result of exposure to the fibers is within the acceptable range, even for a worst case scenario.
RIVM also acknowledges that there are "a number of uncertainties" in its analyses, owing to the fact that the toxicity studies used as reference relate to inhalation exposure to smaller sized fibers. However, despite these uncertainties, RIVM says it expects the actual risks from the fibers to be lower than the risks calculated in the report.
MHRA
RIVM, Report
Tags: Silimed, Sientra, Breast Implants
Regulatory Focus newsletters
All the biggest regulatory news and happenings.